Amanote Research
Register
Sign In
Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma
Hematological Oncology
- United Kingdom
doi 10.1002/hon.15_2629
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Cancer Research
Oncology
Hematology
Date
June 1, 2019
Authors
Y. Song
K. Zhou
D. Zou
J. Zhou
J. Hu
H. Yang
H. Zhang
J. Ji
W. Xu
J. Jin
F. Lv
R. Feng
S. Gao
D. Zhou
H. Guo
A. Wang
R. Elstrom
J. Huang
W. Novotny
L. Han
J. Zhu
Publisher
Wiley
Related search
Durable Response With Single-Agent Acalabrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Leukemia
Cancer Research
Oncology
Anesthesiology
Pain Medicine
Hematology
Outcomes in First Relapsed-Refractory Younger Patients With Mantle Cell Lymphoma: Results From the Mantle-First Study
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Multicenter Phase II Study of Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Phase 2 Trial of Rituximab and Bortezomib in Patients With Relapsed or Refractory Mantle Cell and Follicular Lymphoma
Cancer
Cancer Research
Oncology
Safety and Preliminary Efficacy in Patients With Relapsed/Refractory Mantle Cell Lymphoma Receiving Lisocabtagene Maraleucel in Transcend NHL 001
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Differential Effects of BTK Inhibitors Ibrutinib and Zanubrutinib on NK Cell Effector Function in Patients With Mantle Cell Lymphoma
Haematologica
Hematology
A Phase II Study of Carfilzomib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma
British Journal of Haematology
Hematology
Venetoclax (Ven) in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma (Nhl)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Outcomes of Autologous Stem Cell Transplantation (ASCT) in Patients With Relapsed/Refractory HIV-associated Lymphoma
Bone Marrow Transplantation
Transplantation
Hematology
